These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 7981581)

  • 21. Oral melphalan pharmacokinetics--relation to dose in patients with multiple myeloma.
    Ehrsson H; Eksborg S; Osterborg A; Mellstedt H; Lindfors A
    Med Oncol Tumor Pharmacother; 1989; 6(2):151-4. PubMed ID: 2747308
    [TBL] [Abstract][Full Text] [Related]  

  • 22. High-dose intravenous melphalan for plasma-cell leukaemia and myeloma.
    McElwain TJ; Powles RL
    Lancet; 1983 Oct; 2(8354):822-4. PubMed ID: 6137651
    [TBL] [Abstract][Full Text] [Related]  

  • 23. High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma: a single institution experience at All India Institute of Medical Sciences, New Delhi, using non-cryopreserved peripheral blood stem cells.
    Kayal S; Sharma A; Iqbal S; Tejomurtula T; Cyriac SL; Raina V
    Clin Lymphoma Myeloma Leuk; 2014 Apr; 14(2):140-7. PubMed ID: 24342104
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Intravenous melphalan and dexamethasone followed by lymphoblastoid alpha interferon in higher risk multiple myeloma patients.
    Petrucci MT; La Verde G; Ribersani M; Avvisati G; Mandelli F
    Leuk Lymphoma; 2000 Sep; 39(1-2):131-8. PubMed ID: 10975391
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Influence of renal failure on myelosuppressive effects of melphalan: Cancer and Leukemia Group B experience.
    Cornwell GG; Pajak TF; McIntyre OR; Kochwa S; Dosik H
    Cancer Treat Rep; 1982 Mar; 66(3):475-81. PubMed ID: 7060036
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Acute renal failure after excretory urography in diabetic patients.
    Diaz-Buxo JA; Wagoner RD; Hattery RR; Palumbo PJ
    Ann Intern Med; 1975 Aug; 83(2):155-8. PubMed ID: 1147447
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Intermediate dose of intravenous melphalan in advanced multiple myeloma.
    Tsakanikas S; Papanastasiou K; Stamatelou M; Maniatis A
    Oncology; 1991; 48(5):369-71. PubMed ID: 1745483
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Interferon alfa-2b/melphalan/prednisone in previously untreated patients with multiple myeloma: a phase I-II trial.
    Cooper MR; Fefer A; Thompson J; Case DC; Kempf R; Sacher R; Neefe J; Bickers J; Scarffe JH; Spiegel RJ
    Invest New Drugs; 1987; 5 Suppl():S41-6. PubMed ID: 3597002
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pharmacology of intravenous melphalan in patients with multiple myeloma.
    Brox L; Birkett L; Belch A
    Cancer Treat Rev; 1979 Jun; 6 Suppl():27-32. PubMed ID: 498169
    [No Abstract]   [Full Text] [Related]  

  • 30. [Withdrawal of maintenance dialysis in a patient with diagnosed multiple myeloma and renal failure as a consequence of effective anti-tumor treatment].
    Rosa J; Sydor A; Jurczyszyn A; Zabawa-Hołyś S; Nowak J; Czapkowicz-Gryszkiewicz L; Sułowicz W
    Przegl Lek; 2010; 67(7):547-50. PubMed ID: 21387773
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prospective randomized placebo-controlled study of granulocyte-macrophage colony-stimulating factor without stem-cell transplantation after high-dose melphalan in patients with multiple myeloma.
    Moreau P; Fiere D; Bezwoda WR; Facon T; Attal M; Laporte JP; Colombat P; Haak HL; Monconduit M; Lockhorst H; Girault D; Harousseau JL
    J Clin Oncol; 1997 Feb; 15(2):660-6. PubMed ID: 9053491
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Intermediate-dose (25 mg/m2) intravenous melphalan for patients with multiple myeloma in relapse or refractory to standard treatment.
    Petrucci MT; Avvisati G; Tribalto M; Cantonetti M; Giovangrossi P; Mandelli F
    Eur J Haematol; 1989 Mar; 42(3):233-7. PubMed ID: 2924885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral versus intravenous melphalan and prednisone treatment in multiple myeloma stage II. A randomized study from the Myeloma Group of Central Sweden.
    Osterborg A; Ahre A; Björkholm M; Björeman M; Brenning G; Gahrton G; Grimfors G; Gyllenhammar H; Hast R; Johansson B
    Acta Oncol; 1990; 29(6):727-31. PubMed ID: 2223143
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concomitant mobilization of plasma cells and hematopoietic progenitors into peripheral blood of patients with multiple myeloma.
    Lemoli RM; Cavo M; Fortuna A
    J Hematother; 1996 Aug; 5(4):339-49. PubMed ID: 8877709
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Synergism of dopamine and furosemide in diuretic-resistant, oliguric acute renal failure.
    Lindner A
    Nephron; 1983; 33(2):121-6. PubMed ID: 6835459
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Glomerular filtration rate prior to high-dose melphalan 200 mg/m(2) as a surrogate marker of outcome in patients with myeloma.
    Sirohi B; Powles R; Kulkarni S; Rudin C; Saso R; Rigg A; Horton C; Singhal S; Mehta J; Treleaven J
    Br J Cancer; 2001 Aug; 85(3):325-32. PubMed ID: 11487259
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Intermediate-dose cyclophosphamide and granulocyte colony-stimulating factor is a valid alternative to high-dose cyclophosphamide for mobilizing peripheral blood CD34+ cells in patients with multiple myeloma.
    Petrucci MT; Avvisati G; La Verde G; De Fabritiis P; Ribersani M; Palumbo G; De Felice L; Rusignuolo A; Simone F; Meloni G; Mandelli F
    Acta Haematol; 2003; 109(4):184-8. PubMed ID: 12853690
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Oral dosage of melphalan and response to treatment in multiple myeloma.
    Fernberg JO; Johansson B; Lewensohn R; Mellstedt H
    Eur J Cancer; 1990 Mar; 26(3):393-6. PubMed ID: 2141499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Factors associated with recovery of renal function in patients with multiple myeloma who were treated with hemodialysis.
    Katagiri D; Hagiwara S; Minami E; Katsuma A; Masumoto S; Hoshino T; Inoue T; Shibata M; Tada M; Nakamura T; Shimbo T; Hinoshita F
    Nephron Clin Pract; 2011; 117(1):c28-32. PubMed ID: 20689322
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose therapy in patients with plasma cell dyscrasias and renal dysfunction.
    Pineda-Roman M; Tricot G
    Contrib Nephrol; 2007; 153():182-94. PubMed ID: 17075230
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.